<DOC>
	<DOCNO>NCT02578069</DOCNO>
	<brief_summary>Prospective , multi-center , randomize 1:1 single blind trial use NOVA sirolimus elute stent versus Apollo bare metal stent conduct approximately 15 interventional neurology center China . The study sponsor Sino Medical Sciences Technology Inc .</brief_summary>
	<brief_title>First-in-man Trial Evaluating Safety Efficacy NOVA Intracranial Stent</brief_title>
	<detailed_description>The study enroll 264 subject overall two group ( randomize 1:1 ) . The study follow-up occur 1 , 6 12 month post-stent implantation . All patient undergo angiography assessment ( DSA/CTA ) 12 month follow-up . Angiography assessment perform baseline ( pre- post-procedure ) 12 month follow-up .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . 18 75 year age ; 2 . Primary recurrent symptomatic intracranial arteriostenosis internal medicine treatment ( i.e . stroke transient ischemic attack within 90 day treatment least one antithrombotic drug vascular risk factor intervention e.g . hypertensors hypertension hypolipidemics hyperlipidemia ) ; 3 . No transient ischemic attack ( TIA ) ischemic stroke occur within 2 week prior stenting procedure ; 4 . ≥70 % stenosis intracranial responsible vessel DSA angiography ( judge WASID method ) ; 5 . Poor blood circulation side branch responsible vessel area angiography within one week prior stenting procedure : Score blood circulation side branch DSA &lt; 3 blood flow rate peak ≥200cm/s systolic phase transcranial doppler ultrasonic examination ( TCD ) ; apparent side branch compensation responsible vessel area CTA score blood circulation side branch CTA &lt; 2 ; 6 . The target lesion reference diameter must visually estimate ≥2.0 mm diameter , lesion length must &lt; 15 mm ; lesion observe distal vessel ; 7 . Atherosclerosis lesion ; 8. mRS &lt; 3 ; 9 . Written informed consent . 1 . &gt; 70 % intracranial largevessel stenosis beyond responsible vessel ; 2 . &gt; 70 % stenosis observe intracranial largevessel distal responsible vessel &gt; 70 % stenosis observe intracranial/extracranial largevessel proximal responsible vessel ; 3 . Acute ischemic stroke within 3 week ; 4 . Obstruction perforate branch artery skull MRI ; 5 . Intracranial hemorrhage angiopathic area within 6 week ; 6 . Patient treat thrombolytic therapy within 24 hour ; 7 . Patients underwent surgery within 30 day plan surgery within 3 month poststenting procedure ; 8 . Severe calcified lesion ; 9 . Patients treat intracranial/extracranial stenting procedure prior study ; 10 . Nonatherosclerosis lesion ; 11 . Patients potential source cardiac embolism ; 12 . Concomitant intracranial tumor , aneurysm intracranial arteriovenous malformation ; 13 . Known hypersensitivity contraindication aspirin , heparin , antiplatelet medication specify use study , sirolimus , poly ( lacticcoglycolic acid ) polymer , poly ( nbutyl methacrylate ) ; 14 . Hemoglobin &lt; 100g/L , platelet count &lt; 100,000 cells/mm3 , International normalize ratio ( INR ) &gt; 1.5 ( irreversible ) uncorrectable hemorrhagic factor ; 15 . Serious neural dysfunction due responsible angiopathy sequel cerebral infarction ( mRS≥3 ) ; 16 . Known liver renal insufficiency ( ALT &gt; 3x upper limit AST &gt; 3x upper limit , creatinine &gt; 1.5x upper limit ) ; 17 . Life expectancy &lt; 2 year ; 18 . Pregnant/lactating female patient ; 19 . Patients cognitive impairment mental disease ; 20 . The patient participate another investigational device drug study within 3 month ; 21 . Inapplicable intravascular stenting treatment per investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Intracranial Stenting</keyword>
</DOC>